Showing posts with label Microbiology. Show all posts
Showing posts with label Microbiology. Show all posts

Thursday, August 12, 2010

Superbug on the prowl in India, UK scientists warn of worldwide spread


AGENCIES, Aug 11, 2010, 03.46pm IST

LONDON: " Health tourists" flocking to south Asia have carried a new class of antibiotic-resistant superbugs to Britain, researchers reported Wednesday, warning that the bacteria could spread worldwide.

The 
superbug has so far been identified in 37 people who returned to the UK after undergoing surgery inIndia or Pakistan.

Many hospital infections that were already difficult to treat have become even more impervious to drugs due to a recently discovered gene that can jump across different species of bacteria.

This so-called NDM-1 gene was first identified last year by Cardiff University's Timothy 
Walsh in two types of bacteria — Klebsiella pneumoniae and Escherichia coli — in a Swedish patient admitted to hospital in India.

Worryingly, the new NDM-1 bacteria are resistant even to carbapenems, a group of antibiotics often reserved as a last resort for emergency treatment for multi-drug resistant bugs.

Researchers said the bugs had been brought into 
Britain by patients who travelled to India or Pakistan for cosmetic surgery.

"If these infections were allowed to continue without appropriate treatment, then certainly one would expect to see some sort of mortality," Walsh, a microbiology professor, told 
BBC radio.

"It's going to be very difficult to treat the infections once the patients present with these types of bacteria. You won't get well."

In the new study, led by Walsh and Madras University's Karthikeyan Kumarasamy, researchers set out to determine how common the NDM-1 producing bacteria were in South Asia and Britain, where several cases had turned up.

Checking hospital patients with suspect symptoms, they found 44 cases — 1.5 per cent of those screened — in Chennai, and 26 (eight percent of those screened) in Haryana, both in India.

They likewise found the superbug in Bangladesh and Pakistan, as well as 37 cases in Britain, some in patients who had recently returned from having cosmetic surgery in India or Pakistan.

"India also provides cosmetic surgery for other Europeans and Americans, and it is likely that NDM-1 will spread worldwide," said the study, published in British medical journal The Lancet.

NDM-1 was mostly found in E. coli, a common source of community-acquired urinary tract infections, and K. pneumoniae, and was impervious to all antibiotics except two, tigecycline and colistin.

In some cases, even these drugs did not beat back the infection.

"We've actually almost run out of antibiotics. We only have two left and one isn't particularly good," Walsh told the BBC.

Crucially, the NDM-1 gene was found on DNA structures, called plasmids that can be easily copied and transferred between bacteria, giving the bug "an alarming potential to spread and diversify," the authors said.

"Unprecedented air travel and migration allow bacterial plasmids and clones to be transported rapidly between countries and continents," they said, adding that most could remain undetected.

The emergence of these new drug-resistant strains could become a serious global public health problem as the major threat shifts toward a broad class of bacteria — including those armed with the NDM-1 gene — known as "Gram-negative", the researchers warn.

"There are few new anti-Gram-negative antibiotics in development, and none that are effective against NDM-1," the study said.

NDM-1 stands for 
New Delhi metallo-beta-lactamase-1.

"We believe it's present within the community within India — not just within the hospitals," Walsh said.

The professor said that looking ahead to what might be available to treat NDM-1, "there are no new antibiotics that are going to be available in 10 years' time".

He added: "We desperately need — in the 21st century it sounds ridiculous that we don't have — a globally-funded surveillance system.

"Secondly, there is a desperate need for new and novel antibiotics targeted towards these types of bacteria."

Saturday, May 15, 2010

Spit-n-send DNA tests spark row in US


WASHINGTON: Some folks are salivating at the prospect while others are spitting fire. A trendy bio-tech company's move to sell through retail outlets a genetic test kit that can assess users' predisposition to various diseases has sparked off a furious debate in America over its ethical and moral dimensions.

Using the $20-$30 (around Rs 1,500) 'Spit Kit', customers can mail a dab of their sputum to labs for tests that will examine DNA variations to determine their risk of getting heart disease, diabetes, various forms of cancer, besides their reaction to common drugs.

The tests will separately cost up to $300, depending on the range and depth of information sought.

Pathway Genomics, a San Diego start-up, had announced on Tuesday that it would start selling the 'Spit Kit' later this week through the nation's 7,500 Walgreen stores. Packaged in a box with the more palatable "Discover Your DNA" imprint, with a stamped envelope enclosed, the spit kit can be mailed back to company. Customers can then go to the Pathways website to order specific tests and pay the required fees. They can also get the results via the Web.

The idea is not novel. Personal genomics companies, mostly Internet-based, have been around for around three years; and drug stores carry individual diagnostic kits for pregnancy, cholesterol, blood sugar, even paternity tests. But Pathway has pushed the envelope by going retail, hoping to trump front-runners such as Navigenics and 23andMe, which are still Internet-based.

The move is already attracting scrutiny from the US Food and Drug Administration (FDA), which says it has not approved or validated the test kit. Ethicists are also concerned. They say learning about predisposed diseases will raise moral issues relating to marriage, childbirth, inheritance, and even business and professional decisions.

"Genetic testing is a complex, difficult and emotionally laden medical process, which requires extensive counselling, contextualization and interpretation," Dr Michael A Grodin, professor of bioethics, human rights, family medicine and psychiatry at Boston University Schools of Medicine and Public Health, said on ABC News, even as arguments raged online.

Medical insurance companies and the clergy are yet to pitch in.

Genomics industry enthusiasts, including a Utah company that has sold over 100,000 paternity DNA tests since it was introduced in March 2008, say such personalized medicine is the wave of the future and people have the right to know, if they want to.

Pathway, on its part, says FDA clearance is not necessary to sell the Spit Kit, because, it insists, the tests are not intended for use in diagnosis, treatment or for the mitigation or cure of a disease. "It does provide information that allows a person to learn about their health to make healthier lifestyle choices," the company said.

Wednesday, April 21, 2010

Spotters in Microbiology


Biphasic Medium

Autoclave



Antibiotic Sensitivity Test

Actinomycosis                                        
Acid Fast Bacilli